About US
Contact us
-
CFDA issues the First Summary of Announcements of Illegal Drug, Medical Device, and Health Food Advertisements in 2013On April 19, 2013, China Food and Drug Administration (CFDA) issued the First Summary of Announcements of Illegal Drug, Medical Device, and Health Food Advertisements in 2013.2013/5/3
-
Even if Actavis buy fails, Valeant looks ready for bigger dealsValeant ($VRX) CEO J. Michael Pearson hasn't made a secret of his ambitions. He wants to be within spitting distance of Big Pharma. Numbers-wise, that means he's shooting for $10 billion in sales, qu2013/5/2
-
First patient treated with new drug for multiple myelomaA patient suffering with multiple myeloma has been treated with a human antibody drug in a phase II clinical trial of BI-505 from BioInvent International. The drug binds to the ICAM-1 adhesion protein2013/5/2
-
Sanofi distances itself from consultant caught up in tax fraud probeSanofi ($SNY), already facing intense criticism for job cuts in France, now finds itself defending the use of a lobbyist who was a consultant to CEO Chris Viehbacher. The company said it is no longer2013/4/27
-
Actavis to make generic tamper-resistant OxyContinPurdue Pharma and generic drugmaker Actavis ($ACT) have settled their patent suit over a special formulation of the painkiller OxyContin just 10 days the FDA banned generic versions that do not carry2013/4/27
-
New Bristol-Myers drug growth cushions plummeting Plavix salesBristol-Myers Squibb ($BMY) chose a good day to report its first-quarter results. AstraZeneca's ($AZN) declining sales and profits help blunt its own disappointments: earnings that dropped 44%, on a2013/4/26
-
European regulators tag 100-plus drugs with 'black triangle'The European Medicines Agency has rolled out its list of drugs that soon will bear the "black triangle." The labeling logo is designed to encourage doctors and patients to report side effects, as par2013/4/26
-
Is GlaxoSmithKline prepping older products for spinoff?GlaxoSmithKline's waiting game continues. The U.K.-based drugmaker ($GSK) posted disappointing profits for the first quarter as sales took a backwards step, partly because of revenue lost in the sale2013/4/25
-
Merck nabs 'breakthrough' label for anti-melanoma drugMerck ($MRK) won the FDA's "Breakthrough Therapy" tag for its experimental antibody drug lambrolizumab, aimed at advanced melanoma. The designation was based on Phase Ib data that showed significant2013/4/25
-
Drugmakers, get ready for bigger, faster dealmaking, Moody's saysDeal junkies, rejoice. Moody's Investors Service figures pharma M&A will pick up in 2013, after a not-so-exciting 2012. But even if the pace picks up, deal size probably won't increase much; we'r2013/4/24